Zalicus slumps as another lead candidate bites the dust
This article was originally published in Scrip
Executive Summary
Zalicus' lead drug candidate Z160 has failed in two Phase II chronic pain trials, prompting the company to terminate its development. The news sent the company's share price into a nose dive. It closed 72% down at $1.30 on the news (11 November).